Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk

Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA., 302, 1993, 10.1001/jama.2009.1619 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N. Engl. J. Med., 357, 1301, 10.1056/NEJMoa064278 Rye, 2009, The metabolism and anti-atherogenic properties of HDL, J. Lipid Res., 50, S195, 10.1194/jlr.R800034-JLR200 Badimon, 1990, Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit, J. Clin. Invest., 85, 1234, 10.1172/JCI114558 Rubin, 1991, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature., 353, 265, 10.1038/353265a0 Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse, Proc. Natl. Acad. Sci. USA., 91, 9607, 10.1073/pnas.91.20.9607 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA., 290, 2292, 10.1001/jama.290.17.2292 Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA., 297, 1675, 10.1001/jama.297.15.jpc70004 Barter, 1980, Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins, J. Lipid Res., 21, 238, 10.1016/S0022-2275(20)39830-8 Barter, 1982, Transfers and exchanges of esterified cholesterol between plasma lipoproteins, Biochem. J., 208, 1, 10.1042/bj2080001 Ha, 1982, Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species, Comp. Biochem. Physiol. B., 71, 265, 10.1016/0305-0491(82)90252-8 Hesler, 1987, Purification and characterization of a human plasma cholesteryl ester transfer protein, J. Biol. Chem., 262, 2275, 10.1016/S0021-9258(18)61650-3 Drayna, 1987, Cloning and sequencing of human cholesteryl ester transfer protein cDNA, Nature., 327, 632, 10.1038/327632a0 Qiu, 2007, Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules, Nat. Struct. Mol. Biol., 14, 106, 10.1038/nsmb1197 Swenson, 1988, Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids, J. Biol. Chem., 263, 5150, 10.1016/S0021-9258(18)60692-1 Tall, 1993, Plasma cholesteryl ester transfer protein, J. Lipid Res., 34, 1255, 10.1016/S0022-2275(20)36957-1 Ihm, 1982, Kinetics of plasma protein-catalyzed exchange of phosphatidylcholine and cholesteryl ester between plasma lipoproteins, J. Lipid Res., 23, 1328, 10.1016/S0022-2275(20)38039-1 Zhang, 2012, Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein, Nat. Chem. Biol., 8, 342, 10.1038/nchembio.796 Barter, 1981, Studies of esterified cholesterol in sub-fractions of plasma high density lipoproteins, Atherosclerosis., 38, 165, 10.1016/0021-9150(81)90113-1 Brown, 1989, Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins, Nature., 342, 448, 10.1038/342448a0 Teh, 1998, Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a Caucasian subject from North America, J. Lipid Res., 39, 442, 10.1016/S0022-2275(20)33905-5 Whitlock, 1989, Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism, J. Clin. Invest., 84, 129, 10.1172/JCI114132 Barter, 2007, Effects of torcetrapib in patients at high risk for coronary events, N. Engl. J. Med., 357, 2109, 10.1056/NEJMoa0706628 Cannon, 2010, Safety of anacetrapib in patients with or at high risk for coronary heart disease, N. Engl. J. Med., 363, 2406, 10.1056/NEJMoa1009744 de Grooth, 2002, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study, Circulation., 105, 2159, 10.1161/01.CIR.0000015857.31889.7B Nicholls, 2011, Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial, JAMA., 306, 2099, 10.1001/jama.2011.1649 Marcel, 1980, Transfer of cholesterol esters between human high density lipoproteins and triglyceride-rich lipoproteins controlled by a plasma protein factor, Atherosclerosis., 35, 127, 10.1016/0021-9150(80)90078-7 Krauss, 2012, Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib, J. Lipid Res., 53, 540, 10.1194/jlr.M018010 Johnson, 1997, Lipoproteins and cellular cholesterol homeostasis, Subcell. Biochem., 28, 235, 10.1007/978-1-4615-5901-6_9 Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J. Clin. Invest., 88, 2039, 10.1172/JCI115532 Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler. Thromb. Vasc. Biol., 15, 1987, 10.1161/01.ATV.15.11.1987 Nicholls, 2005, Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits, Circulation., 111, 1543, 10.1161/01.CIR.0000159351.95399.50 Mineo, 2006, Endothelial and antithrombotic actions of HDL, Circ. Res., 98, 1352, 10.1161/01.RES.0000225982.01988.93 Bisoendial, 2003, Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein, Circulation., 107, 2944, 10.1161/01.CIR.0000070934.69310.1A Tso, 2006, High-density lipoproteins enhance progenitor-mediated endothelium repair in mice, Arterioscler. Thromb. Vasc. Biol., 26, 1144, 10.1161/01.ATV.0000216600.37436.cf Seetharam, 2006, High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I, Circ. Res., 98, 63, 10.1161/01.RES.0000199272.59432.5b Sumi, 2007, Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis, Arterioscler. Thromb. Vasc. Biol., 27, 813, 10.1161/01.ATV.0000259299.38843.64 Abderrahmani, 2007, Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells, Diabetologia., 50, 1304, 10.1007/s00125-007-0642-z Drew, 2009, High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus, Circulation., 119, 2103, 10.1161/CIRCULATIONAHA.108.843219 Westerterp, 2006, Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice, Arterioscler. Thromb. Vasc. Biol., 26, 2552, 10.1161/01.ATV.0000243925.65265.3c Marotti, 1993, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein, Nature., 364, 73, 10.1038/364073a0 Föger, 1999, Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice, J. Biol. Chem., 274, 36912, 10.1074/jbc.274.52.36912 Hayek, 1995, Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene, J. Clin. Invest., 96, 2071, 10.1172/JCI118255 Sugano, 1998, Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits, J. Biol. Chem., 273, 5033, 10.1074/jbc.273.9.5033 Rittershaus, 2000, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 20, 2106, 10.1161/01.ATV.20.9.2106 Okamoto, 2000, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nature., 406, 203, 10.1038/35018119 Morehouse, 2007, Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits, J. Lipid Res., 48, 1263, 10.1194/jlr.M600332-JLR200 Thompson, 2008, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk, JAMA., 299, 2777, 10.1001/jama.299.23.2777 Ridker, 2009, Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18,245 initially healthy women from the Women's Genome Health Study, Circ. Cardiovasc. Genet., 2, 26, 10.1161/CIRCGENETICS.108.817304 Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., . Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. Epub ahead of print. May 17, 2012; doi:10.1016/S0140-6736(12)60312-2. Curb, 2004, A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly, J. Lipid Res., 45, 948, 10.1194/jlr.M300520-JLR200 Moriyama, 1998, A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency, Prev. Med., 27, 659, 10.1006/pmed.1998.0340 Clark, 2006, Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action, J. Lipid Res., 47, 537, 10.1194/jlr.M500349-JLR200 Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis, N. Engl. J. Med., 356, 1304, 10.1056/NEJMoa070635 Kastelein, 2007, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia, N. Engl. J. Med., 356, 1620, 10.1056/NEJMoa071359 Bots, 2007, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial, Lancet., 370, 153, 10.1016/S0140-6736(07)61088-5 Barter, 2009, Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, Am. J. Cardiol., 104, 10E, 10.1016/j.amjcard.2009.09.014 Yvan-Charvet, 2007, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL, Arterioscler. Thromb. Vasc. Biol., 27, 1132, 10.1161/ATVBAHA.106.138347 Nicholls, 2008, Circulation., 118, 2506, 10.1161/CIRCULATIONAHA.108.790733 Forrest, 2008, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone, Br. J. Pharmacol., 154, 1465, 10.1038/bjp.2008.229 Hu, 2009, Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition, Endocrinology., 150, 2211, 10.1210/en.2008-1512 Clerc, 2010, Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels, J. Hypertens., 28, 1676, 10.1097/HJH.0b013e32833b1f8e Sofat, 2010, Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms, Circulation., 121, 52, 10.1161/CIRCULATIONAHA.109.865444 Connelly, 2010, Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition, J. Cardiovasc. Pharmacol., 55, 459, 10.1097/FJC.0b013e3181cf03cb Simic, B., Hermann, M., Shaw, S. G., Bigler, L., Stalder, U., Dorries, C., Besler, C., Luscher, T. F., Ruschitzka, F., . Torcetrapib impairs endothelial function in hypertension. Eur. Heart J., Epub ahead of print. September 14, 2011; doi: 10.1093/eurheartj/ehr348. Barter, 2011, Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, Circulation., 124, 555, 10.1161/CIRCULATIONAHA.111.018259 Kuivenhoven, 2005, Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia, Am. J. Cardiol., 95, 1085, 10.1016/j.amjcard.2004.12.064 Niesor, 2010, Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport, J. Lipid Res., 51, 3443, 10.1194/jlr.M008706 Stroes, 2009, Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats, Br. J. Pharmacol., 158, 1763, 10.1111/j.1476-5381.2009.00460.x Fayad, 2011, Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial, Lancet., 378, 1547, 10.1016/S0140-6736(11)61383-4 Hermann, 2009, The hypertension peril: lessons from CETP inhibitors, Curr. Hypertens. Rep., 11, 76, 10.1007/s11906-009-0014-9 Lüscher, 2012, Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial, Eur. Heart J., 33, 857, 10.1093/eurheartj/ehs019 Schwartz, 2009, Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome, Am. Heart J., 158, 896, 10.1016/j.ahj.2009.09.017 Castro-Perez, 2011, Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters, J. Lipid Res., 52, 1965, 10.1194/jlr.M016410 Ranalletta, 2010, Biochemical characterization of cholesteryl ester transfer protein inhibitors, J. Lipid Res., 51, 2739, 10.1194/jlr.M007468 Cao, 2011, Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure, J. Lipid Res., 52, 2169, 10.1194/jlr.M018069 Boettcher, 2012, Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein, Br. J. Clin. Pharmacol., 73, 210, 10.1111/j.1365-2125.2011.04083.x Yvan-Charvet, 2010, Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib, Arterioscler. Thromb. Vasc. Biol., 30, 1430, 10.1161/ATVBAHA.110.207142 Liu, 1994, Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice, J. Lipid Res., 35, 2263, 10.1016/S0022-2275(20)39932-6 Barter, 1982, A unified model of esterified cholesterol exchanges between human plasma lipoproteins, Atherosclerosis., 44, 27, 10.1016/0021-9150(82)90050-8 Lagrost, 1992, Cholesteryl ester transfer protein promotes the association of HDL apolipoproteins A-I and A-II with LDL: potentiation by oleic acid, Biochim. Biophys. Acta., 1127, 255, 10.1016/0005-2760(92)90229-O Maruyama, 2003, Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia, Atherosclerosis., 166, 177, 10.1016/S0021-9150(02)00327-1 Nagano, 2002, Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay, J. Lipid Res., 43, 1011, 10.1194/jlr.M200024-JLR200 Ritsch, 1997, Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma, Arterioscler. Thromb. Vasc. Biol., 17, 3433, 10.1161/01.ATV.17.12.3433 Fryirs, 2010, Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion, Arterioscler. Thromb. Vasc. Biol., 30, 1642, 10.1161/ATVBAHA.110.207373 Plump, 1999, Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 MacLean, 2003, Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice, Arterioscler. Thromb. Vasc. Biol., 23, 1412, 10.1161/01.ATV.0000080687.94313.67